INTRODUCTION

Diabetic nephropathy is a leading cause of end-stage renal disease throughout the world. The establishment of novel, effective therapeutic strategies is, therefore, urgently required. Proteinuria and/or albuminuria is a sign of glomerular lesions in diabetic nephropathy. These lesions can subsequently develop into tubulointerstitial lesions that lead to renal dysfunction [1]. Clinically, therefore, reducing proteinuria is considered a principal therapeutic target to improve renal outcomes in patients with diabetic nephropathy.

The pathogenesis of diabetic nephropathy involves altered intracellular metabolism associated with hyperglycemia, including the activation of protein kinase C, the accumulation of advanced glycation end-products, increased flux of the polyol pathway and oxidative stress [23456]. Moreover, hemodynamic changes such as systemic and glomerular hypertension related to hyperactivation of the renin-angiotensin system are involved in diabetic nephropathy [7]. The strong association of these alterations with the pathogenesis of diabetic nephropathy has been supported by a number of large clinical trials such as the Diabetes Control and Complications Trial (DCCT), United Kingdom Prospective Diabetes Study (UKPDS), Kumamoto study and Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENNAL) study, all of which showed that intensive control of glycemia and blood pressure with the blockades of renin-angiotensin system could successfully prevent the progression of diabetic nephropathy [78910]. Furthermore, interestingly, recent clinical studies have revealed that microalbuminuria was reversible and overt proteinuria partially reversible with strict glycemic and blood pressure controls [1112]. Thus, some aspects of diabetic nephropathy are becoming treatable. However, it is also an undeniable fact that some patients develop treatment-resistant proteinuria, such as nephrotic syndrome, resulting in end stage renal disease. Thus, additional therapeutic options are needed to further reduce proteinuria and/or to protect proximal tubular cells from proteinuria-related toxicity.

Compared with several proteinuric kidney diseases, the renal prognosis of patients with diabetic nephropathy is extremely poor. This suggests that the diabetic condition makes various renal cells vulnerable to damage. Cells have evolved several mechanisms to cope with stress and to maintain cellular homeostasis, such as the anti-oxidative stress response [5] and the endoplasmic reticulum (ER) stress response [13]. In addition, autophagy is an intracellular catabolic processes, in which proteins and organelles are degraded via lysosomes to maintain intracellular homeostasis under certain cytotoxic stress conditions, including hypoxia and ER stress [14]. Recent reports have shown that autophagy activity declines with obesity or aging in some organs, a decline that is associated with the pathogenesis of obesity- and age-related diseases [1516]. The functional roles of autophagy in the kidney have been intensely investigated [17]. For example, autophagy has been reported to play renoprotective roles during both normal aging and after acute kidney injury in some animal models [1819]. These findings allow us to hypothesize that diabetes can impair autophagic activity, making kidney cells vulnerable to diabetes-related metabolic stress and to consider autophagy as a new therapeutic target for diabetic nephropathy [20]. In this review, we summarize recent experimental findings regarding the role of autophagy in diabetic nephropathy and discuss its therapeutic potential.

AUTOPHAGY

The term "autophagy" is derived from Greek, and means self-eating. It is a bulk degradation process involved in the clearance of damaged proteins and organelles and is a highly conserved process from yeast to mammals [21]. Autophagy has two major physiological roles in cells. One is to recycle intracellular energy resources in response to conditions of nutrient depletion [22], and the other is to remove cytotoxic proteins and damaged organelles under various stress conditions [14]. Thus, autophagy is recognized as an essential system to maintain cellular homeostasis. Several types of autophagy have been described, including macroautophagy, microautophagy, and chaperone-mediated autophagy, all of which differ in their mechanisms and functions. Of these three types, macroautophagy is the most prevalent and is hereafter referred to as autophagy.

During autophagy, de novo isolation membranes (phagophores) elongate and fuse while engulfing a portion of the cytoplasm within double-membraned vesicles (autophagosomes) [21]. Autophagosomes can originate from the ER membranes. Four major steps are involved in the formation of autophago-somes: initiation, nucleation, elongation, and closure [21], each of which is strictly regulated by proteins encoded by autophagy-related genes (Atgs).

Autophagy is initiated by activation of the unc-51-like kinase 1 (Ulk1) complex, the mammalian ortholog of the yeast Atg1 complex. The Ulk1 complex is composed of the Ulk1 Ser/Thr protein kinase, Atg13 and FIP200, the mammalian homolog of the yeast Atg17 protein. Ulk1-mediated phosphorylation of Atg13 and FIP200 is essential for triggering autophagy. Phago-phore nucleation is dependent on a Beclin1 (Atg6 in yeast), hVps34 complex, or class III phosphatidylinositol 3-kinase (PI3K) complex, which consists of Beclin1, hVps34, hVps15, and Atg14 [2324]. Autophagosome elongation/closure involves two ubiquitin-like conjugation systems: Atg12 and light chain 3 (LC3), the mammalian ortholog of yeast Atg8. The Atg12-Atg5 conjugate, which forms the Atg12-Atg5-Atg16 complex, contributes to the stimulation and localization of the LC3 conjugation reaction. The cytosolic isoform of LC3 (LC3-I) is conjugated to phosphatidylethanolamine through two consecutive ubiquitination-like reactions catalyzed by the E1-like enzyme Atg7 and the E2-like enzyme Atg3, forming LC3-II. Thus, LC3-II formation is recognized as a marker for autophagosomes in cell and animal experiments [21]. After formation, the autophagosomes merge with lysosomal compartments to form autolysosomes. Finally, autophagosome containing macromolecules can be degraded by lysosome enzymes. The protein p62, also known as sequestosome 1 (SQSTM1), localizes to autophagosomes by interacting with LC3 and is consistently degraded by the autophagy-lysosome system [25]. The accumulation of p62 has been observed in autophagy-deficient cells [25].

NUTRITION-RELATED REGULATORY MECHANISM OF AUTOPHAGY

Autophagy is triggered by nutrient starvation conditions and functions to overcome such a life-threatening situation. Thus, the signaling associated with autophagy is mostly understood in the context of coping with nutritional stress and maintaining cellular homeostasis. Many studies have concentrated on amino acid and insulin-dependent signaling involving mammalian target of rapamycin complex 1 (mTORC1). Hyperactivation of mTORC1 due to amino acid load or insulin stimulation can inhibit autophagy at the step of autophagy initiation [26]. Upstream of mTORC1, 5'-adenosine monophosphate (AMP)-activated protein kinase (AMPK) phosphorylates and activates tuberous sclerosis 2, an inhibitor of mTORC1, in response to a low adenosine triphosphate/AMP ratio, leading to mTORC1 inactivation and autophagy induction [27]. Furthermore, under glucose starvation, AMPK promotes autophagy by directly activating Ulk1 through phosphorylation of Ser317 and Ser777 [28]. In contrast, under nutrient sufficiency, high mTORC1 activity prevents Ulk1 activation by phosphorylating Ulk1 Ser757 and disrupting the interaction between Ulk1 and AMPK [28]. This coordinated phosphorylation is important for Ulk1 in autophagy induction. Thus, mTORC1 and AMPK play central and opposite roles in regulating the initiation of autophagy in response to alterations in intra- and extra-cellular nutrient levels (Fig. 1).

Sirt1 is a nicotinamide adenine dinucleotide (NAD)-dependent deacetylase that can also act as an intracellular nutrient sensing signal through its deacetylase activity on some tran scriptional factors and cytosolic proteins [29]. Sirt1 is activated under energy depleted conditions in response to an increase in the ratio of NAD/NADH. Sirt1 can directly deacetylate some Atg proteins, such as Atg5, Atg7, and Atg8, and this process is required for starvation-induced autophagy activation [30]. Furthermore, Sirt1 deacetylates forkhead box O3a (FOXO3a), which results in upregulation of Bnip3 gene transcription, resulting in Beclin-1-dependent initiation of autophagy [19]. Thus, Sirt1 regulates autophagosome formation via multiple components of the autophagy machinery (Fig. 1).

AUTOPHAGY ACTIVITY IN RENAL CELLS

As mentioned above, once autophagy is activated, LC3 proteins localize to the autophagosome membrane. This can be observed in a transgenic mouse carrying a green fluorescent protein (GFP)-LC3 fusion transgene as a green dot signal and, therefore, activation of autophagy can be detected in cells of the transgenic mouse [31]. This animal model is widely employed and we used it to examine autophagy activity in kidneys. As previously reported [31], podocytes show active autophagy regardless of feeding condition (Fig. 2). In contrast, proximal tubular cells show autophagy activation only when they were exposed to starvation (Fig. 2). Using the GFP-LC3 mouse model, we did not find autophagosome dots in renal cells other than podocytes and proximal tubular cells, for example in cells of the distal tubules and collecting duct. These results are consistent with recent reports from other investigators. Thus, podocytes and proximal tubular cells are the focus of autophagy studies in the field of kidney research.

PODOCYTE AUTOPHAGY IN DIABETIC NEPHROPATHY

Proteinuria is a major clinical concern of diabetic nephropathy and is caused by disruption to the glomerular filtration barrier. Glomerular epithelial cells, also called podocytes, are predominantly responsible for maintaining the glomerular filtration barrier [32]. Podocytes are highly specialized, terminally differentiated and unable to proliferate. Podocyte loss due to cell death and podocyte foot process dysfunction result in massive proteinuria in diabetic nephropathy [33]. Thus, maintaining podocyte cell homeostasis is regarded as a therapeutic target to prevent progression to nephrotic syndrome due to diabetic nephropathy.

The autophagy-lysosomal degradation pathway is likely to play an essential role in maintaining podocyte function. As mentioned above, podocytes exhibit active autophagy even under non-stress conditions, suggesting that podocytes require a high basal level of autophagy to maintain cellular homeostasis [31]. Podocyte-specific autophagy-deficient mice, resulting from Atg5 gene deletion, have glomerular lesions accompanied by podocyte loss and albuminuria that increase with age [18]. Furthermore, the impairment of lysosomal function in podocytes by deletion of the mammalian target of rapamycin (mTOR), prorenin receptor or mVps34 genes caused severe glomerular sclerosis, massive proteinuria [343536]. Since autophagy involves degradation by lysosomes, autophagosomal degradation was disturbed in the podocytes of these mouse models. These results support the idea that the autophagy-lysosomal degradation pathway plays an essential role in maintaining podocyte cell homeostasis.

Despite this knowledge of the physiological role of podocyte autophagy, the role of autophagy in diabetic nephropathy has remained unclear. However, accumulating evidence now shows an association between autophagy and diabetic nephropathy. Autophagic activity in podocytes of streptozotocin-induced diabetic mice was found to decline with increased duration of diabetes [37]. Cultured podocytes exposed to high concentrations of glucose also showed lower autophagic activity, along with decreased levels of autophagy-related proteins, such as beclin-1 and the Atg5-Atg12 complex [37]. Furthermore, suppression of beclin-1 expression in cultured podocytes decreased podocin expression resulting in albumin leakage [37]. These findings suggest that hyperglycemia reduces autophagy activity, leading to alterations in podocyte function and disturbance to the glomerular filtration barrier.

Although many of these results support the hypothesis that autophagy is involved in the pathogenesis of diabetic nephropathy, direct evidence showing the involvement of autophagy in the pathogenesis of diabetic nephropathy using podocyte-specific autophagy deficient animals had not been reported until recently. However, two recent works, including our own, have clearly shown the renoprotective role of autophagy in diabetic podocytes [3839]. Podocyte-specific autophagy-deficient mice developed podocyte loss and massive proteinuria when used in a high-fat diet (HFD)-induced obese type 2 diabetic model [38]. Furthermore, deletion of Atg5 specifically in podocytes resulted in accelerated diabetes-induced podocytopathy with a leaky glomerular filtration barrier in a streptozotocin-induced type 1 diabetic model [39]. Collectively, these findings suggest that autophagy is likely to play an essential role in coping with diabetic stress in podocytes, regardless of whether the diabetic nephropathy is type 1 or type 2.

What is the degradation target of podocyte autophagy? As mentioned previously, lysosomes are likely to be important in maintaining podocyte homeostasis. In our recent study, a massive accumulation of lysosomes with abnormal morphology was observed in the podocytes of obese type 2 diabetic rodents with autophagy deficiency [38]. Although it remains unclear whether lysosomes are a unique target of podocyte autophagy under any pathogenic conditions, our results suggest that damaged lysosomes are an important degradation target of podocyte autophagy, at least under diabetic conditions.

AUTOPHAGY IN PROXIMAL TUBULAR CELLS

Compared with most other glomerular diseases, the renal outcomes of patients with diabetic nephropathy are extremely poor and the underlying mechanisms remain unclear. The severity of proteinuria-induced tubulointerstitial lesions is strongly correlated with renal outcomes regardless of the cause of the glomerular disease [14041]; therefore, diabetic conditions may exacerbate proteinuria-induced tubulointerstitial lesions compared with other primary glomerular diseases [42]. If so, identifying the detailed molecular mechanisms underlying the diabetes- and/or obesity-mediated vulnerability of proximal tubular cells may contribute to the development of new therapies that can improve renal outcomes in obese type 2 diabetes patients with persistent proteinuria. Is autophagy involved in the mechanism of diabetes-related vulnerability in proximal tubular cells? In this section, we discuss this possibility based on several recent publications.

The physiological role of autophagy in proximal tubular cells differs from its role in podocytes. Autophagy activity is very low in proximal tubular cells under basal conditions, but higher rates of autophagy are required by cells under stress conditions. Acute kidney injury due to nephrotoxic agents and ischemia is becoming a serious health problem in clinical settings. A great number of recent animal studies have shown that autophagy in proximal tubular cells is enhanced during acute kidney injury caused by ischemic-reperfusion and cisplatin, a nephrotoxic anti-cancer drug [434445]. Furthermore, mice lacking autophagy activity in proximal tubular cells, generated by deleting the Atg5 and Atg7 genes, showed progressive renal damage, suggesting that activation of autophagy during acute kidney injury is renoprotective [434446]. These mice also showed premature renal aging, suggesting that a low level of basal autophagy is essential to keep cell homeostasis in proximal tubular cells, or that autophagy induction is needed to cope with age-related extra- and intra-cellular stresses, such as hypoxia and ER stress.

Proteinuria creates strong nephrotoxic stress in a number of proteinuric kidney diseases, including diabetic nephropathy [140]. Based on our previous paper, an increased flux of protein into the urinary lumen from the glomeruli was found to activate autophagy in proximal tubular cells, which reabsorb the protein in urinary lumen. Atg5 knockout mice, deficient in proximal tubular cell-specific autophagy, developed severe proteinuria-induced tubulointerstitial lesions, along with enhanced proximal tubular cell apoptosis, similar to results obtained in animal models of acute kidney injury [47]. Collectively, proximal tubular cells can induce autophagy to cope with both acute and chronic nephrotoxic stresses. Thus, autophagy in proximal tubular cells and podocytes plays a renoprotective role in various stages of proteinuric kidney diseases.

Studies have also assessed the effects of obesity and diabetes on renoprotective autophagy in proximal tubular cells exposed to nephrotoxicity. Autophagy activity was shown to be significantly suppressed in the kidneys of streptozotocin-induced diabetic mice, HFD-induced obese mice and Wistar fatty rats [4748]. This led to the accumulation of damaged molecules and organelles, including p62 protein and damaged mitochondria, which are normally degraded via the autophagy-lysosomal pathway. Interestingly, autophagy insufficiency has been confirmed in renal biopsies of patients with obese type 2 diabetes [47]. The proximal tubular cells of patients with type 2 diabetes showed the accumulation of p62 protein, suggesting that deficient autophagy also occurs in humans with obesity type 2 diabetes.

The mechanism involved in autophagy-deficient proximal tubular cells of obese animals and humans has also been investigated. As mentioned in the previous section, autophagy is regulated by intracellular nutrient signals, such as mTORC1, AMPK, and Sirt1. Of these signals, mTORC1 is likely to be involved in diabetes-related inhibition of stress-induced autophagy in proximal tubular cells [47]. Histological analysis showed that the proximal tubular cells of obese type 2 diabetic mice and humans were intensely positive for phosphorylated S6 protein, an indicator of mTORC1 activation, and strongly associated with an obesity-related deficiency in autophagy [47]. These findings indicate that autophagy deficiency and the pathogenesis of diabetic nephropathy are closely associated. Obesity- or diabetes-mediated autophagy deficiency is likely to be involved in the vulnerability of proximal tubular cells (Fig. 3). Restoring autophagy activity may therefore be a new therapeutic strategy for diabetic patients with overt proteinuria.

AUTOPHAGY IN OTHER RENAL CELLS

Diabetes primarily injures endothelial cells, which is strongly associated with the initiation of diabetic nephropathy. Lenoir et al. [39] have shown direct evidence of the association between endothelial cell autophagy and diabetic nephropathy. They showed that endothelial cell-specific autophagy-deficient mice develop severe glomerular damage, indicating that autophagy in the endothelium also plays a renoprotective role against diabetic stress. Thus, although autophagy activity was not apparent in these cells from studying GFP-LC3 transgenic mice, cell-specific autophagy-deficient mice can provide im portant information regarding autophagy in diabetic nephropathy in renal cells other than podocytes and proximal tubular cells. This area is being actively researched and the role of diabetic autophagy in mesangial cells, distal tubular cells and collecting duct is under scrutiny.

THERAPEUTIC STRATEGIES TARGETING THE ACTIVATION OF AUTOPHAGY

The evolution of autophagy has enabled it to be activated under nutrient-depleted conditions, to overcome long-term periods of starvation. For the past several decades, many investigators have tried to identify calorie restriction-mediated anti-aging effects in mammals. Activation of autophagy is essential for calorie restriction-mediated life span elongation and anti-aging effects in various organisms [4950]. Autophagy in proximal tubular cells is activated by short-term starvation, suggesting that these cells possess a mechanism by which autophagy is induced in response to energy depletion. Calorie restriction has a renoprotective action against several kinds of renal injury [1951]. A calorie restriction regimen, which activates autophagy, should therefore become a potent therapeutic strategy to prevent diabetic nephropathy. Indeed, calorie restriction improves renal damage in type 2 diabetic Wistar fatty rats, as well as restoring autophagy activity in their proximal tubular cells [48]. Thus, an agent that can mimic caloric restriction may have potency to activate autophagy in mammalian cells, and become a therapy for diabetic nephropathy.

Given that autophagy is regulated by nutrient-responsive intracellular signals such as mTORC1, AMPK, and Sirt1, agents that can modify the activity of these signals may have therapeutic potency to treat diabetic nephropathy. Indeed, an mTORC1 inhibitor, rapamycin, improved glomerular lesions in experimental diabetic nephropathy, and it can activate autophagy; therefore, autophagy may be involved in the renoprotective mechanism of rapamycin in diabetic nephropathy. However, excessive mTORC1 inhibition also led to podocyte dysfunction [52]. Thus, whether mTORC1 inhibition is safe and effective for all patients with diabetic nephropathy is still under debate.

AMPK is a nutrient-sensing kinase that positively regulates autophagy. AMPK is activated under conditions of energy depletion and is likely suppressed in diabetic nephropathy [53]. Thus, AMPK-mediated induction of autophagy may be involved in its renoprotective mechanism. AMPK activation may be linked to autophagy for maintaining renal homeostasis in diabetic kidneys. AMPK is inactivated by dephosphorylation in the glomeruli and tubules of both type 1 and type 2 diabetic animal models. This inactivation is reversed by agents such as metformin and resveratrol, along with the attenuation of diabetic glomerular and tubular injury [5354555657]. Decreases in AMPK activity may be involved in the pathogenesis of diabetic nephropathy by reducing autophagy, suggesting that AMPK activation may be a target for restoring autophagy activity, even in diabetic kidneys. Some agents, such as 5-aminoimidazole-4-carboxamide ribonucleotide and metformin, can improve renal lesions in experimental diabetic nephropathy models. These agents might improve diabetic nephropathy through the restoration of autophagy activity in diabetic kidneys.

Sirt1 is another regulator of autophagy. A recent study has shown that Sirt1 deficiency is associated with the pathogenesis of both podocyte injury and proximal tubular cell damage in diabetic nephropathy, and that re-activation of this deacetylase improved diabetic nephropathy in mice [58]. We previously reported that an age-dependent decline of Sirt1 activity caused suppression of stress-induced autophagy in mouse kidneys, which accelerated the premature aging renal phenotype [19]. Thus, diabetes-related decline of Sirt1 activity may lead to inhibition of autophagy, leading to a severe renal phenotype in diabetic nephropathy. Taken together, these findings suggest that nutrient-sensing signals are strong candidate targets for modifying autophagy activity in kidney. However, direct evidence is still lacking and revealing the relationship among these signals, autophagy, and pathogenesis of diabetic nephropathy is a challenge that remains to be completed.

CONCLUSIONS

Over a period of decades, a large number of studies have attempted to reveal the molecular mechanisms underlying diabetic nephropathy and to develop new therapeutic strategies. However, the incidence of end-stage renal disease due to diabetic nephropathy continues to increase worldwide. There is an urgent need to identify new therapies for diabetic nephropathy. We have provided a perspective on the involvement of autophagy in the pathogenesis of diabetic nephropathy and whether it can be a new therapeutic target to treat this condition. The study of autophagy in diabetic nephropathy has only recently begun; therefore, evidence showing its involvement in the pathogenesis of diabetic nephropathy is still emerging. A great number of issues remain to be resolved. Future studies will provide clear evidence to determine whether autophagy should be considered a novel therapeutic target for diabetic nephropathy, and we hope that this review can contribute to the study of autophagy in diabetic nephropathy.

Acknowledgements

ACKNOWLEDGMENTS

This review manuscript supported by Grants-in-Aid for Scientific Research (KAKENHI) from the Japan Society for the Promotion of Science (No. 25713033 to SK, and No. 25670414 and No. 70242980 to DK); from the Takeda Science Foundation (to SK); from the Banyu Life Science Foundation International (to SK).

NOTES

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

REFERENCES

• 1. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol 2006;17:2974-2984. ArticlePubMed
• 2. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615-1625. PubMed
• 3. Dunlop M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int Suppl 2000;77:S3-S12. ArticlePubMed
• 4. Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G, Cooper ME. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 2003;17:1762-1764. ArticlePubMedPDF
• 5. Ha H, Hwang IA, Park JH, Lee HB. Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. Diabetes Res Clin Pract 2008;82(Suppl 1):S42-S45. ArticlePubMed
• 6. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998;47:859-866. ArticlePubMedPDF
• 7. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S;. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869. ArticlePubMed
• 8. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986. ArticlePubMed
• 9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853. ArticlePubMed
• 10. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117. ArticlePubMed
• 11. Araki S, Haneda M, Sugimoto T, Isono M, Isshiki K, Kashiwagi A, Koya D. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 2005;54:2983-2987. ArticlePubMedPDF
• 12. Yokoyama H, Araki S, Honjo J, Okizaki S, Yamada D, Shudo R, Shimizu H, Sone H, Moriya T, Haneda M. Association between remission of macroalbuminuria and preservation of renal function in patients with type 2 diabetes with overt proteinuria. Diabetes Care 2013;36:3227-3233. ArticlePubMedPMCPDF
• 13. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007;8:519-529. ArticlePubMedPDF
• 14. Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell 2010;40:280-293. ArticlePubMedPMC
• 15. Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, Tanaka K, Cuervo AM, Czaja MJ. Autophagy regulates lipid metabolism. Nature 2009;458:1131-1135. ArticlePubMedPMCPDF
• 16. Yoshizaki T, Kusunoki C, Kondo M, Yasuda M, Kume S, Morino K, Sekine O, Ugi S, Uzu T, Nishio Y, Kashiwagi A, Maegawa H. Autophagy regulates inflammation in adipocytes. Biochem Biophys Res Commun 2012;417:352-357. ArticlePubMed
• 17. Huber TB, Edelstein CL, Hartleben B, Inoki K, Jiang M, Koya D, Kume S, Lieberthal W, Pallet N, Quiroga A, Ravichandran K, Susztak K, Yoshida S, Dong Z. Emerging role of autophagy in kidney function, diseases and aging. Autophagy 2012;8:1009-1031. ArticlePubMedPMC
• 18. Hartleben B, Godel M, Meyer-Schwesinger C, Liu S, Ulrich T, Kobler S, Wiech T, Grahammer F, Arnold SJ, Lindenmeyer MT, Cohen CD, Pavenstadt H, Kerjaschki D, Mizushima N, Shaw AS, Walz G, Huber TB. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J Clin Invest 2010;120:1084-1096. ArticlePubMedPMC
• 19. Kume S, Uzu T, Horiike K, Chin-Kanasaki M, Isshiki K, Araki S, Sugimoto T, Haneda M, Kashiwagi A, Koya D. Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. J Clin Invest 2010;120:1043-1055. ArticlePubMedPMC
• 20. Kume S, Thomas MC, Koya D. Nutrient sensing, autophagy, and diabetic nephropathy. Diabetes 2012;61:23-29. ArticlePubMedPDF
• 21. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell 2011;147:728-741. ArticlePubMed
• 22. Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, Yoshimori T, Ohsumi Y, Tokuhisa T, Mizushima N. The role of autophagy during the early neonatal starvation period. Nature 2004;432:1032-1036. ArticlePubMedPDF
• 23. Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, Levine B. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999;402:672-676. ArticlePubMedPDF
• 24. Pattingre S, Espert L, Biard-Piechaczyk M, Codogno P. Regulation of macroautophagy by mTOR and Beclin 1 complexes. Biochimie 2008;90:313-323. ArticlePubMed
• 25. Komatsu M, Waguri S, Koike M, Sou YS, Ueno T, Hara T, Mizushima N, Iwata J, Ezaki J, Murata S, Hamazaki J, Nishito Y, Iemura S, Natsume T, Yanagawa T, Uwayama J, Warabi E, Yoshida H, Ishii T, Kobayashi A, Yamamoto M, Yue Z, Uchiyama Y, Kominami E, Tanaka K. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 2007;131:1149-1163. ArticlePubMed
• 26. Hosokawa N, Hara T, Kaizuka T, Kishi C, Takamura A, Miura Y, Iemura S, Natsume T, Takehana K, Yamada N, Guan JL, Oshiro N, Mizushima N. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell 2009;20:1981-1991. ArticlePubMedPMC
• 27. Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 2011;13:1016-1023. ArticlePubMedPMCPDF
• 28. Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 2011;13:132-141. ArticlePubMedPMCPDF
• 29. Bordone L, Guarente L. Calorie restriction, SIRT1 and metabolism: understanding longevity. Nat Rev Mol Cell Biol 2005;6:298-305. ArticlePubMedPDF
• 30. Lee IH, Cao L, Mostoslavsky R, Lombard DB, Liu J, Bruns NE, Tsokos M, Alt FW, Finkel T. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci U S A 2008;105:3374-3379. ArticlePubMedPMC
• 31. Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell 2004;15:1101-1111. ArticlePubMedPMC
• 32. Kawachi H, Miyauchi N, Suzuki K, Han GD, Orikasa M, Shimizu F. Role of podocyte slit diaphragm as a filtration barrier. Nephrology (Carlton) 2006;11:274-281. PubMed
• 33. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, Meyer TW. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997;99:342-348. ArticlePubMedPMC
• 34. Chen J, Chen MX, Fogo AB, Harris RC, Chen JK. mVps34 deletion in podocytes causes glomerulosclerosis by disrupting intracellular vesicle trafficking. J Am Soc Nephrol 2013;24:198-207. ArticlePubMedPMC
• 35. Cina DP, Onay T, Paltoo A, Li C, Maezawa Y, De Arteaga J, Jurisicova A, Quaggin SE. Inhibition of MTOR disrupts autophagic flux in podocytes. J Am Soc Nephrol 2012;23:412-420. ArticlePubMedPMC
• 36. Oshima Y, Kinouchi K, Ichihara A, Sakoda M, Kurauchi-Mito A, Bokuda K, Narita T, Kurosawa H, Sun-Wada GH, Wada Y, Yamada T, Takemoto M, Saleem MA, Quaggin SE, Itoh H. Prorenin receptor is essential for normal podocyte structure and function. J Am Soc Nephrol 2011;22:2203-2212. ArticlePubMedPMC
• 37. Fang L, Zhou Y, Cao H, Wen P, Jiang L, He W, Dai C, Yang J. Autophagy attenuates diabetic glomerular damage through protection of hyperglycemia-induced podocyte injury. PLoS One 2013;8:e60546ArticlePubMedPMC
• 38. Tagawa A, Yasuda M, Kume S, Yamahara K, Nakazawa J, Chin-Kanasaki M, Araki H, Araki SI, Koya D, Asanuma K, Kim EH, Haneda M, Kajiwara N, Hayashi K, Ohashi H, Ugi S, Maegawa H, Uzu T. Impaired podocyte autophagy exacerbates proteinuria in diabetic nephropathy. Diabetes 2015 9 17 [Epub]. ArticlePDF
• 39. Lenoir O, Jasiek M, Henique C, Guyonnet L, Hartleben B, Bork T, Chipont A, Flosseau K, Bensaada I, Schmitt A, Masse JM, Souyri M, Huber TB, Tharaux PL. Endothelial cell and podocyte autophagy synergistically protect from diabetes-induced glomerulosclerosis. Autophagy 2015;11:1130-1145. ArticlePubMedPMC
• 40. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992;20:1-17. ArticlePubMed
• 41. Risdon RA, Sloper JC, De Wardener HE. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 1968;2:363-366. ArticlePubMed
• 42. Mallamaci F, Ruggenenti P, Perna A, Leonardis D, Tripepi R, Tripepi G, Remuzzi G, Zoccali C. ACE inhibition is renoprotective among obese patients with proteinuria. ACE inhibition is renoprotective among obese patients with proteinuria. J Am Soc Nephrol 2011;22:1122-1128. ArticlePubMedPMC
• 43. Kimura T, Takabatake Y, Takahashi A, Kaimori JY, Matsui I, Namba T, Kitamura H, Niimura F, Matsusaka T, Soga T, Rakugi H, Isaka Y. Autophagy protects the proximal tubule from degeneration and acute ischemic injury. J Am Soc Nephrol 2011;22:902-913. ArticlePubMedPMC
• 44. Liu S, Hartleben B, Kretz O, Wiech T, Igarashi P, Mizushima N, Walz G, Huber TB. Autophagy plays a critical role in kidney tubule maintenance, aging and ischemia-reperfusion injury. Autophagy 2012;8:826-837. ArticlePubMed
• 45. Yang C, Kaushal V, Shah SV, Kaushal GP. Autophagy is associated with apoptosis in cisplatin injury to renal tubular epithelial cells. Am J Physiol Renal Physiol 2008;294:F777-F787. ArticlePubMed
• 46. Takahashi A, Kimura T, Takabatake Y, Namba T, Kaimori J, Kitamura H, Matsui I, Niimura F, Matsusaka T, Fujita N, Yoshimori T, Isaka Y, Rakugi H. Autophagy guards against cisplatin-induced acute kidney injury. Am J Pathol 2012;180:517-525. ArticlePubMed
• 47. Yamahara K, Kume S, Koya D, Tanaka Y, Morita Y, Chin-Kanasaki M, Araki H, Isshiki K, Araki S, Haneda M, Matsusaka T, Kashiwagi A, Maegawa H, Uzu T. Obesity-mediated autophagy insufficiency exacerbates proteinuria-induced tubulointerstitial lesions. J Am Soc Nephrol 2013;24:1769-1781. ArticlePubMedPMC
• 48. Kitada M, Takeda A, Nagai T, Ito H, Kanasaki K, Koya D. Dietary restriction ameliorates diabetic nephropathy through anti-inflammatory effects and regulation of the autophagy via restoration of Sirt1 in diabetic Wistar fatty (fa/fa) rats: a model of type 2 diabetes. Exp Diabetes Res 2011;2011:908185ArticlePubMedPMCPDF
• 49. Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, Allison DB, Cruzen C, Simmons HA, Kemnitz JW, Weindruch R. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009;325:201-204. ArticlePubMedPMC
• 50. Fontana L, Partridge L, Longo VD. Extending healthy life span: from yeast to humans. Science 2010;328:321-326. ArticlePubMedPMC
• 51. Cherry , Engelman RW, Wang BY, Kinjoh K, El-Badri NS, Good RA. Calorie restriction delays the crescentic glomerulonephritis of SCG/Kj mice. Proc Soc Exp Biol Med 1998;218:218-222. ArticlePubMed
• 52. Inoki K, Mori H, Wang J, Suzuki T, Hong S, Yoshida S, Blattner SM, Ikenoue T, Ruegg MA, Hall MN, Kwiatkowski DJ, Rastaldi MP, Huber TB, Kretzler M, Holzman LB, Wiggins RC, Guan KL. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest 2011;121:2181-2196. ArticlePubMedPMC
• 53. Kume S, Uzu T, Araki S, Sugimoto T, Isshiki K, Chin-Kanasaki M, Sakaguchi M, Kubota N, Terauchi Y, Kadowaki T, Haneda M, Kashiwagi A, Koya D. Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet. J Am Soc Nephrol 2007;18:2715-2723. ArticlePubMed
• 54. Chang CC, Chang CY, Wu YT, Huang JP, Yen TH, Hung LM. Resveratrol retards progression of diabetic nephropathy through modulations of oxidative stress, proinflammatory cytokines, and AMP-activated protein kinase. J Biomed Sci 2011;18:47ArticlePubMedPMCPDF
• 55. Takiyama Y, Harumi T, Watanabe J, Fujita Y, Honjo J, Shimizu N, Makino Y, Haneda M. Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1alpha expression and oxygen metabolism. Diabetes 2011;60:981-992. PubMedPMC
• 56. Ding DF, You N, Wu XM, Xu JR, Hu AP, Ye XL, Zhu Q, Jiang XQ, Miao H, Liu C, Lu YB. Resveratrol attenuates renal hypertrophy in early-stage diabetes by activating AMPK. Am J Nephrol 2010;31:363-374. ArticlePubMedPDF
• 57. Lee MJ, Feliers D, Mariappan MM, Sataranatarajan K, Mahimainathan L, Musi N, Foretz M, Viollet B, Weinberg JM, Choudhury GG, Kasinath BS. A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol 2007;292:F617-F627. ArticlePubMed
• 58. Hasegawa K, Wakino S, Simic P, Sakamaki Y, Minakuchi H, Fujimura K, Hosoya K, Komatsu M, Kaneko Y, Kanda T, Kubota E, Tokuyama H, Hayashi K, Guarente L, Itoh H. Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes. Nat Med 2013;19:1496-1504. ArticlePubMedPMCPDF

Fig. 1

Nutrient regulation of autophagy. Autohagosome formation is regulated by a number of autophagy-related proteins at multiple steps. Initiation of autophagy via Ulk1 complex is negatively and positively regulated by mammalian target of rapamycin complex 1 (mTORC1)- and 5'-AMP-activated protein kinase (AMPK)-dependent phosphorylation, respectively. Sirt1-dependent deacetylation is also involved in the activation of autophagy. Origin of autophagosome membrane is endoplasmic reticulum (ER) membrane. Autophagosome fuses with lysosome to form autolysosome and is finally degraded by lysosome enzymes. NAD, nicotinamide adenine dinucleotide; AMP, adenosine monophosphate; ATP, adenosine triphosphate; Atg, autophagy-related gene; LC3, light chain 3; Ulk1, unc-51-like kinase 1; PE, phosphatidylethanolamine; FOXO3a, forkhead box O3a.

Fig. 2

Autophagy activity determined using green fluorescent protein light chain 3 (GFP-LC3) transgenic mouse. Autopphagome can be detected as GFP-LC3 dots in tissues of this mouse model. Autophagosomes formation is constitutively observed in podocytes even under ad-libitum condition. In contrast, autophagy can be observed in proximal tubular cells exposed to 48-hour fasting. The white dotted line box indicates the area for each enlarged figure. Blue signal, DAPI stain to visualize nuclei. Red signal, nidogen stain to visualize basement membrane. Green signal, GFP signal indicating LC3 protein.

Fig. 3

Podocytes and proximal tubular cells have basal and stress-responsive autophagy, which is essential to maintain cellular homeostasis. Some pathological situations such as diabetes, obesity, and aging suppresses both basal and stress-responsive autophagy, leading to massive proteinuria and severe tubular cell damage.

Figure & Data

References

Citations

Citations to this article as recorded by  

• Aging and Diabetic Kidney Disease: Emerging Pathogenetic Mechanisms and Clinical Implications
  Yi Chen, Yashpal S. Kanwar, Xueqin Chen, Ming Zhan
  Current Medicinal Chemistry.2024; 31(6): 697.     CrossRef
• Metformin inhibits high glucose‐induced apoptosis of renal podocyte through regulating miR‐34a/SIRT1 axis
  Xudong Zhuang, Zhuye Sun, Huasheng Du, Tianhui Zhou, Jing Zou, Wei Fu
  Immunity, Inflammation and Disease.2024;[Epub]     CrossRef
• Placenta-derived mesenchymal stem cells protect against diabetic kidney disease by upregulating autophagy-mediated SIRT1/FOXO1 pathway
  Honghong Liu, Jiao Wang, Guanru Yue, Jixiong Xu
  Renal Failure.2024;[Epub]     CrossRef
• Epigenetic Regulation of Autophagy in Bone Metabolism
  Yazhou Zhang, Qianqian Wang, Hongjia Xue, Yujin Guo, Shanshan Wei, Fengfeng Li, Linqiang Gong, Weiliang Pan, Pei Jiang
  Function.2024;[Epub]     CrossRef
• The interaction between lncRNAs and transcription factors regulating autophagy in human cancers: A comprehensive and therapeutical survey
  Saade Abdalkareem Jasim, Yasir Qasim Almajidi, Reyadh R. Al‐Rashidi, Ahmed Hjazi, Irfan Ahmad, Ahmed Hussien Radie Alawadi, Enas R. Alwaily, Hashem O. Alsaab, Ali Haslany, Mohamood Hameed
  Cell Biochemistry and Function.2024;[Epub]     CrossRef
• The beneficial effects of astragaloside IV on ameliorating diabetic kidney disease
  Yiwei Gao, Xin Su, Taiqi Xue, Ning Zhang
  Biomedicine & Pharmacotherapy.2023; 163: 114598.     CrossRef
• #2601 THE MOLECULAR EFFECT OF SGLT2I ON THE AUTOPHAGY PATHWAY IN TYPE II DIABETES MELLITUS AND ITS VASCULAR COMPLICATIONS
  Offir Ertracht, Raneen Saad, Hagar Tadmor, Farid Nakhoul, Nakhoul Nakhoul
  Nephrology Dialysis Transplantation.2023;[Epub]     CrossRef
• Role of oxidative stress in diabetes-induced complications and their management with antioxidants
  Hasandeep Singh, Rajanpreet Singh, Arshdeep Singh, Harshbir Singh, Gurpreet Singh, Sarabjit Kaur, Balbir Singh
  Archives of Physiology and Biochemistry.2023; : 1.     CrossRef
• Stress can affect mitochondrial energy metabolism and AMPK/SIRT1 signaling pathway in rats
  An-ran Zhao, Jie Li, Si-qi Wang, Li-hua Bian, Wen-jing Li, Jian-you Guo
  Brain Research Bulletin.2023; 203: 110770.     CrossRef
• Emerging links between FOXOs and diabetic complications
  Urvi M. Parmar, Manjiri P. Jalgaonkar, Aayush J. Kansara, Manisha J. Oza
  European Journal of Pharmacology.2023; 960: 176089.     CrossRef
• Pathophysiology of diabetic kidney disease and autophagy: A review
  Jiawei Yu, Yan Liu, Hongjie Li, Peirong Zhang
  Medicine.2023; 102(30): e33965.     CrossRef
• Microcystin-LR-induced autophagy via miR-282–5p/PIK3R1 pathway in Eriocheir sinensis hepatopancreas
  Yuning Zhang, Jiancao Gao, Liping Cao, Jinliang Du, Gangchun Xu, Pao Xu
  Ecotoxicology and Environmental Safety.2023; 267: 115661.     CrossRef
• Global research trends and hot spots on autophagy and kidney diseases: a bibliometric analysis from 2000 to 2022
  Sinan Ai, Yake Li, Huijuan Zheng, Zhen Wang, Weijing Liu, JiaYin Tao, Yaotan Li, Yaoxian Wang
  Frontiers in Pharmacology.2023;[Epub]     CrossRef
• Administration of mesenchymal stem cells in diabetic kidney disease: mechanisms, signaling pathways, and preclinical evidence
  Yuexin Zhu, Manyu Luo, Xue Bai, Yan Lou, Ping Nie, Shan Jiang, Jicui Li, Bing Li, Ping Luo
  Molecular and Cellular Biochemistry.2022; 477(8): 2073.     CrossRef
• Dictyophora Polysaccharide Attenuates As-Mediated PINK1/Parkin Pathway-Induced Mitophagy in L-02 Cell through Scavenging ROS
  Ting Hu, Ju Lu, Changyan Wu, Tianxiao Duan, Peng Luo
  Molecules.2022; 27(9): 2806.     CrossRef
• Asiatic acid from Cyclocarya paliurus regulates the autophagy–lysosome system via directly inhibiting TGF-β type I receptor and ameliorates diabetic nephropathy fibrosis
  Xuan-xuan Zhang, Yao Liu, Su-su Xu, Ru Yang, Cui-hua Jiang, Li-ping Zhu, Yin-ying Xu, Ke Pan, Jian Zhang, Zhi-qi Yin
  Food & Function.2022; 13(10): 5536.     CrossRef
• Therapeutic Potential of Resveratrol in Diabetic Nephropathy According to Molecular Signaling
  Marziyeh Salami, Raziyeh Salami, Alireza Mafi, Mohammad-Hossein Aarabi, Omid Vakili, Zatollah Asemi
  Current Molecular Pharmacology.2022; 15(5): 716.     CrossRef
• Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria
  Nasir Shah, Vlado Perkovic, Sradha Kotwal
  Expert Review of Clinical Pharmacology.2022; 15(7): 827.     CrossRef
• Autophagy-nutrient sensing pathways in diabetic complications
  Urvi M. Parmar, Manjiri P. Jalgaonkar, Yogesh A. Kulkarni, Manisha J. Oza
  Pharmacological Research.2022; 184: 106408.     CrossRef
• The Molecular Effects of SGLT2i Empagliflozin on the Autophagy Pathway in Diabetes Mellitus Type 2 and Its Complications
  Ranin Saad, Hagar Tadmor, Offir Ertracht, Nakhoul Nakhoul, Farid Nakhoul, Farber Evgeny, Shaul Atar, Bernd Stratmann
  Journal of Diabetes Research.2022; 2022: 1.     CrossRef
• What’s New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent Advances
  Kimio Watanabe, Emiko Sato, Eikan Mishima, Mariko Miyazaki, Tetsuhiro Tanaka
  International Journal of Molecular Sciences.2022; 24(1): 570.     CrossRef
• Autophagy blockade mechanistically links proton pump inhibitors to worsened diabetic nephropathy and aborts the renoprotection of metformin/enalapril
  Dalia Kamal Mostafa, Mohamed Mostafa Khedr, Mervat Kamel Barakat, Amany Abdelbary Abdellatif, Amal Mohamed Elsharkawy
  Life Sciences.2021; 265: 118818.     CrossRef
• Epigenetic modulation of autophagy genes linked to diabetic nephropathy by administration of isorhamnetin in Type 2 diabetes mellitus rats
  Marwa Matboli, Doaa Ibrahim, Amany H Hasanin, Mohamed K Hassan, Eman K Habib, Miram M Bekhet, Ahmed M Afifi, Sanaa Eissa
  Epigenomics.2021; 13(3): 187.     CrossRef
• Yishen capsule promotes podocyte autophagy through regulating SIRT1/NF-κB signaling pathway to improve diabetic nephropathy
  Yuxiang Liu, Wenyuan Liu, Ziyuan Zhang, Yaling Hu, Xiaodong Zhang, Yanyan Sun, Qingqing Lei, Dalin Sun, Ting Liu, Yanjun Fan, Hui Li, Wujie Ding, Jingai Fang
  Renal Failure.2021; 43(1): 128.     CrossRef
• Geniposide Improves Diabetic Nephropathy by Enhancing ULK1-Mediated Autophagy and Reducing Oxidative Stress through AMPK Activation
  Theodomir Dusabimana, Eun Jung Park, Jihyun Je, Kyuho Jeong, Seung Pil Yun, Hye Jung Kim, Hwajin Kim, Sang Won Park
  International Journal of Molecular Sciences.2021; 22(4): 1651.     CrossRef
• Update on diagnosis, pathophysiology, and management of diabetic kidney disease
  Mai Sugahara, Wai Lun Will Pak, Tetsuhiro Tanaka, Sydney C. W. Tang, Masaomi Nangaku
  Nephrology.2021; 26(6): 491.     CrossRef
• Life-Long Hyperbilirubinemia Exposure and Bilirubin Priming Prevent In Vitro Metabolic Damage
  Annalisa Bianco, Serena Pinci, Claudio Tiribelli, Cristina Bellarosa
  Frontiers in Pharmacology.2021;[Epub]     CrossRef
• NADH/NAD+ Redox Imbalance and Diabetic Kidney Disease
  Liang-Jun Yan
  Biomolecules.2021; 11(5): 730.     CrossRef
• Circular RNAs act as regulators of autophagy in cancer
  Zhixia Zhou, Yinfeng Zhang, Jinning Gao, Xiaodan Hao, Chan Shan, Jing Li, Cuiyun Liu, Yin Wang, Peifeng Li
  Molecular Therapy - Oncolytics.2021; 21: 242.     CrossRef
• Sarsasapogenin restores podocyte autophagy in diabetic nephropathy by targeting GSK3β signaling pathway
  Xi-zhi Li, Hong Jiang, Liu Xu, Yi-qi Liu, Jia-wei Tang, Jia-sen Shi, Xiu-juan Yu, Xue Wang, Lei Du, Qian Lu, Cheng-lin Li, Yao-wu Liu, Xiao-xing Yin
  Biochemical Pharmacology.2021; 192: 114675.     CrossRef
• Dietary Restriction for Kidney Protection: Decline in Nephroprotective Mechanisms During Aging
  Nadezda V. Andrianova, Marina I. Buyan, Anastasia K. Bolikhova, Dmitry B. Zorov, Egor Y. Plotnikov
  Frontiers in Physiology.2021;[Epub]     CrossRef
• Induction of PDCD4 by albumin in proximal tubule epithelial cells potentiates proteinuria-induced dysfunctional autophagy by negatively targeting Atg5
  Ezra Kombo Osoro, Xiaojuan Du, Dong Liang, Xi Lan, Riaz Farooq, Fumeng Huang, Wenhua Zhu, Jiajun Ren, Muhammad Sadiq, Lifang Tian, Xudong Yang, Dongmin Li, Shemin Lu
  Biochemistry and Cell Biology.2021; 99(5): 617.     CrossRef
• Overexpressing STAMP2 attenuates diabetic renal injuries via upregulating autophagy in diabetic rats
  Fang-qiang Song, Ming Song, Wei-xuan Ma, Zhan Gao, Yun Ti, Xu Zhang, Bo-ang Hu, Ming Zhong, Wei Zhang, Ying Yu
  Biochemical and Biophysical Research Communications.2021; 579: 47.     CrossRef
• Mitochondrial Regulation of Diabetic Kidney Disease
  Daniel L. Galvan, Koki Mise, Farhad R. Danesh
  Frontiers in Medicine.2021;[Epub]     CrossRef
• Diabetic kidney disease update: Pathogenesis and treatment overview for clinicians
  Elmukhtar Habas, Abdel-Naser Elzouki
  Journal of Diabetes and Endocrine Practice.2021; 04(03): 107.     CrossRef
• VDR/Atg3 Axis Regulates Slit Diaphragm to Tight Junction Transition via p62-Mediated Autophagy Pathway in Diabetic Nephropathy
  Bin Wang, Jing-yi Qian, Tao-tao Tang, Li-lu Lin, Nan Yu, Hong-lei Guo, Wei-jie Ni, Ling-Li Lv, Yi Wen, Zuo-Lin Li, Min Wu, Jing-Yuan Cao, Bi-Cheng Liu
  Diabetes.2021; 70(11): 2639.     CrossRef
• SIRT1: Mechanism and Protective Effect in Diabetic Nephropathy
  Jing Ji, Pengyu Tao, Qian Wang, Lingxing Li, Yuzhen Xu
  Endocrine, Metabolic & Immune Disorders - Drug Targets.2021; 21(5): 835.     CrossRef
• SIRT1 Alleviates Aldosterone-Induced Podocyte Injury by Suppressing Mitochondrial Dysfunction and NLRP3 Inflammasome Activation
  Mingzhu Jiang, Min Zhao, Mi Bai, Juan Lei, Yanggang Yuan, Songming Huang, Yue Zhang, Guixia Ding, Zhanjun Jia, Aihua Zhang
  Kidney Diseases.2021; 7(4): 293.     CrossRef

• Salvianolic Acid B Improves Chronic Mild Stress-Induced Depressive Behaviors in Rats: Involvement of AMPK/SIRT1 Signaling Pathway

  
  Dehua Liao, Yun Chen, Yujin Guo, Changshui Wang, Ni Liu, Qian Gong, Yingzhou Fu, Yilan Fu, Lizhi Cao, Dunwu Yao, Pei Jiang
  Journal of Inflammation Research.2020; Volume 13: 195.     CrossRef
• Long non-coding RNAs and pyroptosis
  Dong He, Jun Zheng, Jia Hu, Juan Chen, Xing Wei
  Clinica Chimica Acta.2020; 504: 201.     CrossRef
• Resveratrol ameliorates renal damage by inhibiting oxidative stress-mediated apoptosis of podocytes in diabetic nephropathy
  Fang Wang, Ran Li, Linlin Zhao, Shuang Ma, Guijun Qin
  European Journal of Pharmacology.2020; 885: 173387.     CrossRef
• Beneficial Effect of Chloroquine and Amodiaquine on Type 1 Diabetic Tubulopathy by Attenuating Mitochondrial Nox4 and Endoplasmic Reticulum Stress
  Jun Mo Kang, Hyun-Seob Lee, Junghyun Kim, Dong Ho Yang, Hye Yun Jeong, Yu Ho Lee, Dong-Jin Kim, Seon Hwa Park, MinJi Sung, Jaehee Kim, Hyun-Ju An, Sang Ho Lee, So-Young Lee
  Journal of Korean Medical Science.2020;[Epub]     CrossRef
• Glucagon-like peptide-1 alleviates diabetic kidney disease through activation of autophagy by regulating AMP-activated protein kinase-mammalian target of rapamycin pathway
  Shuangli Yang, Chuman Lin, Xiaoyun Zhuo, Jiyu Wang, Shitao Rao, Wen Xu, Yanzhen Cheng, Li Yang
  American Journal of Physiology-Endocrinology and Metabolism.2020; 319(6): E1019.     CrossRef
• Inhibition of soluble epoxide hydrolase attenuates renal tubular mitochondrial dysfunction and ER stress by restoring autophagic flux in diabetic nephropathy
  Xu-shun Jiang, Xing-yang Xiang, Xue-mei Chen, Jun-ling He, Ting Liu, Hua Gan, Xiao-gang Du
  Cell Death & Disease.2020;[Epub]     CrossRef
• Orientin Protects Podocytes from High Glucose Induced Apoptosis through Mitophagy
  Zi‐Li Kong, Kui Che, Jian‐Xia Hu, Ying Chen, Yun‐Yang Wang, Xiang Wang, Wen‐Shan Lü, Yan‐Gang Wang, Jing‐Wei Chi
  Chemistry & Biodiversity.2020;[Epub]     CrossRef
• Sex-Specific Metabolic Changes in Peripheral Organs of Diabetic Mice
  Xi Zhang, Hangying Xu, Jie Ning, Hui Ji, Junjie Yan, Yafei Zheng, Qingqing Xu, Chen Li, Liangcai Zhao, Hong Zheng, Hongchang Gao
  Journal of Proteome Research.2020; 19(8): 3011.     CrossRef
• Liver X receptor activation induces podocyte injury via inhibiting autophagic activity
  Ziyi Zhang, Shengjie Tang, Weiwei Gui, Xihua Lin, Fenping Zheng, Fang Wu, Hong Li
  Journal of Physiology and Biochemistry.2020; 76(2): 317.     CrossRef
• Autophagy plays a protective role duringPseudomonas aeruginosa-induced apoptosis via ROS–MAPK pathway
  Lu Han, Qinmei Ma, Jialin Yu, Zhaoqian Gong, Chenjie Ma, Yanan Xu, Guangcun Deng, Xiaoling Wu
  Innate Immunity.2020; 26(7): 580.     CrossRef
• Autophagy in diabetic nephropathy: a review
  Elias A. T. Koch, Rola Nakhoul, Farid Nakhoul, Nakhoul Nakhoul
  International Urology and Nephrology.2020; 52(9): 1705.     CrossRef
• P2Y2R contributes to the development of diabetic nephropathy by inhibiting autophagy response
  Theodomir Dusabimana, So Ra Kim, Eun Jung Park, Jihyun Je, Kyuho Jeong, Seung Pil Yun, Hye Jung Kim, Hwajin Kim, Sang Won Park
  Molecular Metabolism.2020; 42: 101089.     CrossRef
• Cardioprotective Effects of Taurisolo® in Cardiomyoblast H9c2 Cells under High-Glucose and Trimethylamine N-Oxide Treatment via De Novo Sphingolipid Synthesis
  Stefania Lama, Vincenzo Monda, Maria Rosaria Rizzo, Marco Dacrema, Maria Maisto, Giuseppe Annunziata, Gian Carlo Tenore, Ettore Novellino, Paola Stiuso, Laura Sartiani
  Oxidative Medicine and Cellular Longevity.2020; 2020: 1.     CrossRef
• Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy
  Yu Ho Lee, Sang Hoon Kim, Jun Mo Kang, Jin Hyung Heo, Dong-Jin Kim, Seon Hwa Park, MinJi Sung, Jaehee Kim, Jisu Oh, Dong Ho Yang, Sang Ho Lee, So-Young Lee
  American Journal of Physiology-Renal Physiology.2019; 317(4): F767.     CrossRef
• Critical role of mitochondrial dysfunction and impaired mitophagy in diabetic nephropathy
  Sugandh Saxena, Alpana Mathur, Poonam Kakkar
  Journal of Cellular Physiology.2019; 234(11): 19223.     CrossRef
• High Dose Vitamin E Attenuates Diabetic Nephropathy via Alleviation of Autophagic Stress
  Yuxue Zhao, Wenting Zhang, Qi Jia, Zhendong Feng, Jing Guo, Xueting Han, Yuning Liu, Hongcai Shang, Yaoxian Wang, Wei Jing Liu
  Frontiers in Physiology.2019;[Epub]     CrossRef
• Caffeic Acid Modulates miR-636 Expression in Diabetic Nephropathy Rats
  Ahmed M. Salem, Aya S. Ragheb, Marwa G. A. Hegazy, Marwa Matboli, Sanaa Eissa
  Indian Journal of Clinical Biochemistry.2019; 34(3): 296.     CrossRef
• Mechanistic Understanding of the Engineered Nanomaterial-Induced Toxicity on Kidney
  Haiyang Zhao, Luxin Li, Huilu Zhan, Yanhui Chu, Bingbing Sun
  Journal of Nanomaterials.2019; 2019: 1.     CrossRef
• Diabetic nephropathy: An update on pathogenesis and drug development
  Vikram Rao A/L B Vasanth Rao, Sean Hong Tan, Mayuren Candasamy, Subrat Kumar Bhattamisra
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(1): 754.     CrossRef
• Luteolin attenuates high glucose-induced podocyte injury via suppressing NLRP3 inflammasome pathway
  Qian Yu, Minda Zhang, Lifen Qian, Dan Wen, Guanzhong Wu
  Life Sciences.2019; 225: 1.     CrossRef
• Catalpol Ameliorates Podocyte Injury by Stabilizing Cytoskeleton and Enhancing Autophagy in Diabetic Nephropathy
  Yan Chen, Qingpu Liu, Zengfu Shan, Wangyang Mi, Yingying Zhao, Meng Li, Baiyan Wang, Xiaoke Zheng, Weisheng Feng
  Frontiers in Pharmacology.2019;[Epub]     CrossRef
• Role of sirtuin-1 in diabetic nephropathy
  Wanning Wang, Weixia Sun, Yanli Cheng, Zhonggao Xu, Lu Cai
  Journal of Molecular Medicine.2019; 97(3): 291.     CrossRef
• Energy restriction in renal protection
  Si-Yang Wang, Guang-Yan Cai, Xiang-Mei Chen
  British Journal of Nutrition.2018; 120(10): 1149.     CrossRef
• The dysregulated autophagy signaling is partially responsible for defective podocyte development in wt1a mutant zebrafish
  Xuemei Zhang, Qiaohong Lin, Fan Ren, Jin Zhang, Farman Ullah Dawar, Jie Mei
  Aquaculture and Fisheries.2018; 3(3): 99.     CrossRef
• Supplementation of Abelmoschus manihot Ameliorates Diabetic Nephropathy and Hepatic Steatosis by Activating Autophagy in Mice
  Hwajin Kim, Theodomir Dusabimana, So Kim, Jihyun Je, Kyuho Jeong, Min Kang, Kye Cho, Hye Kim, Sang Park
  Nutrients.2018; 10(11): 1703.     CrossRef
• Acute Kidney Injury and Progression of Diabetic Kidney Disease
  Samuel Mon-Wei Yu, Joseph V. Bonventre
  Advances in Chronic Kidney Disease.2018; 25(2): 166.     CrossRef
• Cardioprotective effects of dietary rapamycin on adult female C57BLKS/J‐Leprdb mice
  Peter C. Reifsnyder, Sergey Ryzhov, Kevin Flurkey, Rea P. Anunciado‐Koza, Ian Mills, David E. Harrison, Robert A. Koza
  Annals of the New York Academy of Sciences.2018; 1418(1): 106.     CrossRef
• Viability of primary cultured podocytes is associated with extracellular high glucose-dependent autophagy downregulation
  Irena Audzeyenka, Dorota Rogacka, Agnieszka Piwkowska, Stefan Angielski, Maciej Jankowski
  Molecular and Cellular Biochemistry.2017; 430(1-2): 11.     CrossRef
• Autophagy Protects against Palmitic Acid-Induced Apoptosis in Podocytes in vitro
  Xu-shun Jiang, Xue-mei Chen, Jiang-min Wan, Hai-bo Gui, Xiong-zhong Ruan, Xiao-gang Du
  Scientific Reports.2017;[Epub]     CrossRef
• Apelin involved in progression of diabetic nephropathy by inhibiting autophagy in podocytes
  Yu Liu, Jia Zhang, Yangjia Wang, Xiangjun Zeng
  Cell Death & Disease.2017; 8(8): e3006.     CrossRef
• Autophagy and its link to type II diabetes mellitus
  Jai-Sing Yang, Chi-Cheng Lu, Sheng-Chu Kuo, Yuan-Man Hsu, Shih-Chang Tsai, Shih-Yin Chen, Yng-Tay Chen, Ying-Ju Lin, Yu-Chuen Huang, Chao-Jung Chen, Wei-De Lin, Wen-Lin Liao, Wei-Yong Lin, Yu-Huei Liu, Jinn-Chyuan Sheu, Fuu-Jen Tsai
  BioMedicine.2017; 7(2): 8.     CrossRef
• Resveratrol protects podocytes against apoptosis via stimulation of autophagy in a mouse model of diabetic nephropathy
  Shan-Shan Huang, Da-Fa Ding, Sheng Chen, Cheng-Long Dong, Xiao-Long Ye, Yang-Gang Yuan, Ya-Min Feng, Na You, Jia-Rong Xu, Heng Miao, Qiang You, Xiang Lu, Yi-Bing Lu
  Scientific Reports.2017;[Epub]     CrossRef
• Long non-coding RNAs involved in autophagy regulation
  Lixian Yang, Hanying Wang, Qi Shen, Lifeng Feng, Hongchuan Jin
  Cell Death & Disease.2017; 8(10): e3073.     CrossRef
• Treatment of diabetic kidney disease: current and future targets
  Mi-Kyung Kim
  The Korean Journal of Internal Medicine.2017; 32(4): 622.     CrossRef
• MiR-30c protects diabetic nephropathy by suppressing epithelial-to-mesenchymal transition in db/db mice
  Yanru Zhao, Zhongwei Yin, Huaping Li, Jiahui Fan, Shenglan Yang, Chen Chen, Dao Wen Wang
  Aging Cell.2017; 16(2): 387.     CrossRef